Articles Archive - Page 57 of 814

FDA Approves New Biosimilar for Adult & Pediatric Arthritis

Michele B. Kaufman, PharmD, BCGP | November 6, 2023

This year, tocilizumab biosimilars have been approved to treat adult and pediatric patients with rheumatic disease, including rheumatoid arthritis, juvenile idiopathic arthritis and more, in both Europe and the U.S.

Special Interests in Rheumatology: What are your peers saying about laboratory testing, practice & workforce issues at ACR Convergence 2023?

Keri Losavio | November 3, 2023

ACR Convergence 2023 offers so much more than scientific sessions. If you have a special interest in a topic, this is the place to be. Consider these opportunities: Lab Tests Open Meeting Sunday, Nov. 12, 10–11 a.m. PST Location: Sapphire E Room, Hilton San Diego Bayfront Attendees interested in laboratory testing issues are invited to…

‘Better Equipped to Serve the College’: A Look at CORC Achievements Through the Pandemic

Carina Stanton | November 3, 2023

Outgoing CORC Chair Marcus Snow, MD, FACR, and the College look back on the tremendous achievements made during the past three years, including pandemic care guidance, improved patient access to care and direction through new biosimilars choices.

FDA Approves Canakinumab to Treat Gout Flares

Michele B. Kaufman, PharmD, BCGP | November 3, 2023

Canakinumab has received FDA approval for the treatment of patients with acute gout flares.

Concerning the Back: Updates in AS & nr-axSpA

Jason Liebowitz, MD, FACR | November 2, 2023

During the 19th Annual Johns Hopkins Advances in the Diagnosis and Treatment of the Rheumatic Diseases Symposium, Dr. Atul Deodhar provided an overview on axial spondyloarthritis (axSpA) and non-radiographic axSpA, with helpful insights into the diagnosis and care of patients with these conditions.

FDA Accepts NDA for Investigational RA Agent

Michele B. Kaufman, PharmD, BCGP | November 1, 2023

The FDA has accepted an investigational new drug application (NDA) for MYMD-1, an oral tumor necrosis factor-α inhibitor for patients with rheumatoid arthritis.

When Is Arthroplasty Recommended? New ACR/AAHKS Guideline Offers Considerations for Timing of Elective Hip or Knee Arthroplasty

Ruth Jessen Hickman, MD | November 1, 2023

The ACR released a new arthroplasty guideline in an effort to remedy significant & detrimental delays faced by osteoarthritis or osteonecrosis patients who require surgical intervention.